Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vitamin D in Bronchiolitis Obliterans Syndrome (VIT001)

This study has been completed.
Katholieke Universiteit Leuven
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven Identifier:
First received: September 28, 2010
Last updated: November 10, 2015
Last verified: October 2013
Vitamin D deficiency occurs in around 50% of our transplant population. Preventive treatment with Vitamin D (D-cure) can reduce the prevalence of Bronchiolitis Obliterans Syndrome after lung transplantation

Condition Intervention Phase
Allograft Rejection
Lung Transplantation
Bronchiolitis Obliterans
Drug: Vitamin D
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation

Resource links provided by NLM:

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • Prevalence of Bronchiolitis Obliterans syndrome (BOS) (grade 1) at 2 years after transplantation [ Time Frame: 2 years after transplantation ]
    BOS= decline in forced expiratory volume in 1 second (FEV1) with at least 80% compared to the best post-operative value

  • Prevalence of BOS (grade 1) at 3 years after transplantation [ Time Frame: 3 years after transplantation ]
    her-evaluation of data

Secondary Outcome Measures:
  • Bronchoalveolar lavage [ Time Frame: during 2 and 3y of follow-up ]
    cellularity, protein and mRNA concentration and microbiology

  • Peripheral blood [ Time Frame: During 2 and 3 years of follow-up ]
    Protein and mRNA concentration, cellularity

  • Rejection rates [ Time Frame: During 2 and 3 years of follow-up ]
    Acute rejection and lymphocytic bronchiolitis rates

  • Reflux [ Time Frame: During 2 and 3 years of follow-up ]
    clinical and biochemical approach

  • Infection rates [ Time Frame: During 2 and 3 years of follow-up ]
    cytomegalovirus (CMV) and non- CMV infection rates

Enrollment: 100
Study Start Date: October 2010
Study Completion Date: August 2015
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Olive oil
Drug: Vitamin D
Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
Other Name: D-Cure
Experimental: Vitamin D
Addition of D-cure (100.000U) to standard care
Drug: Vitamin D
Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
Other Name: D-Cure

Detailed Description:
  • Prospective, interventional, randomized, double-blind, placebo-controlled trial.
  • Clinical setting (tertiary University Hospital).
  • Investigator-driven, no pharmaceutical sponsor.
  • Lung transplant recipients.
  • Add-on of study-drug (placebo or vitamin D) to 'standard of care' (standardized, routine immunosuppressive and infectious prophylactic protocol).
  • 1:1 inclusion ratio (placebo:Vitamin D).
  • Randomisation at discharge after informed consent.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable LTx recipients at discharge after transplantation.
  • Signed informed consent
  • Adult (age at least 18 years old at moment of transplantation)
  • Able to take oral medication

Exclusion Criteria:

  • Prolonged and/or complicated Intensive care unit-course after transplantation.
  • Early (<30 days post-transplant) post-operative death
  • Major suture problems (airway stenosis or stent)
  • Retransplantation (lung)
  • Previous transplantation (solid organ)
  • Multi-organ transplantation (lung+ other solid organ)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01212406

UZ Gasthuisberg
Leuven, Belgium, 3000
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Katholieke Universiteit Leuven
Principal Investigator: Geert M Verleden, MD, PhD UZ gasthuisberg
  More Information

Responsible Party: Universitaire Ziekenhuizen Leuven Identifier: NCT01212406     History of Changes
Other Study ID Numbers: VIT001
Study First Received: September 28, 2010
Last Updated: November 10, 2015

Keywords provided by Universitaire Ziekenhuizen Leuven:
Organ rejection
Lung transplantation
Bronchiolitis Obliterans
Vitamin D

Additional relevant MeSH terms:
Bronchiolitis Obliterans
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on May 24, 2017